DelveInsight’s “Fibromyalgia Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Fibromyalgia pipeline landscapes. It comprises Fibromyalgia pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Fibromyalgia therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Fibromyalgia pipeline products.
Some of the key takeaways of the Fibromyalgia Pipeline Report
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Forest Pharmaceuticals, Pfizer Pharmaceuticals, Innovativemed concepts, Aptinyx, Astellas Pharma, etc., are developing therapies for the treatment of Fibromyalgia.
Emerging therapies such as Savella, LYRICA, IMC-1, NYX-2925, ASP0819, are expected to have a significant impact on the Fibromyalgia market in the coming years.
IMC-1 (Innovativemed concepts) is a novel combination antiviral treatment that is designed to suppress the herpes virus. The company is currently planning to initiate a phase III study for the management of Fibromyalgia.
Get an overview of pipeline landscape @ Fibromyalgia Clinical Trials Analysis
Fibromyalgia is a disease in which the member states are widespread musculoskeletal pain accompanied by fatigue, problems with sleep, memory, and mood. Researchers believe that fibromyalgia increases the sensation of pain, the effects in the brain and the spinal cord treatment is painful and does not cause the pain signals.
Fibromyalgia Emerging Drugs
Savella by Forest Pharmaceuticals
LYRICA by Pfizer Pharmaceuticals
IMC-1 by Innovativemed concepts
NYX-2925 by Aptinyx
ASP0819 by Astellas Pharma
And others.
Scope of Fibromyalgia Pipeline Drug Insight
Coverage: Global
Major Players: Forest Pharmaceuticals, Pfizer Pharmaceuticals, Innovativemed concepts, Aptinyx, Astellas Pharma, and others.
Pipeline Therapies: Savella, LYRICA, IMC-1, NYX-2925, ASP0819, and others.
Table of Contents
1
Fibromyalgia Report Introduction
2
Fibromyalgia Executive Summary
3
Fibromyalgia Overview
4
Fibromyalgia- Analytical Perspective In-depth Commercial Assessment
5
Fibromyalgia Pipeline Therapeutics
6
Fibromyalgia Late Stage Products (Phase II/III)
7
Fibromyalgia Mid Stage Products (Phase II)
8
Fibromyalgia Early Stage Products (Phase I)
9
Fibromyalgia Preclinical Stage Products
10
Fibromyalgia Therapeutics Assessment
11
Fibromyalgia Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Fibromyalgia Key Companies
14
Fibromyalgia Key Products
15
Fibromyalgia Unmet Needs
16
Fibromyalgia Market Drivers and Barriers
17
Fibromyalgia Future Perspectives and Conclusion
18
Fibromyalgia Analyst Views
19
Appendix
20
About DelveInsight
Get a customized pipeline report @ Fibromyalgia Drugs Pipeline Report
Related Reports:
Fibromyalgia Market
DelveInsight’s Fibromyalgia – Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the Fibromyalgia, historical and forecasted epidemiology as well as the Fibromyalgia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Fibromyalgia Epidemiology
DelveInsight’s ‘Fibromyalgia- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Fibromyalgia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/